Cue Biopharma
21 Erie Street
Cambridge, MA 02139
United States
110 articles with Cue Biopharma
-
Cue Biopharma to Present at Two February 2023 Scientific Conferences
2/1/2023
Cue Biopharma, Inc. (Nasdaq: CUE) announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference.
-
Cue Biopharma Announces Chief Medical Officer Transition
1/23/2023
Cue Biopharma, Inc. (Nasdaq: CUE) announced today that Matteo Levisetti, M.D., senior vice president (SVP) of clinical development at Cue Biopharma, has been promoted to Chief Medical Officer (CMO) effective January 17, 2023.
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences - November 22, 2022
11/22/2022
Cue Biopharma, Inc. announced that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Summit, to be held virtually December 6-7.
-
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
11/14/2022
Cue Biopharma, Inc. announced today that it has entered into securities purchase agreements with certain accredited investors for a $30 million private investment in public equity (PIPE) financing.
-
Cue Biopharma Reports Third Quarter 2022 Financial Results
11/14/2022
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported third quarter 2022 financial results.
-
Early data from a combination of Cue Biopharma's CUE-101 and Keytruda shows the treatment is effective in patients with recurrent/metastatic HPV16+ head and neck cancer.
-
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
11/10/2022
Cue Biopharma, Inc. announced today the presentation of new positive data from its ongoing Phase 1 trial evaluating its lead interleukin 2 (IL-2)-based biologic, CUE-101 in combination with pembrolizumab (KEYTRUDA), as a first line therapy for patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma (HNSCC).
-
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November 2022
11/9/2022
Cue Biopharma, Inc. announced that it will present at two investor conferences this November, the Stifel Healthcare Conference 2022, to be held November 15-16 in New York, and the Jefferies London Healthcare Conference, to be held in London, UK, November 15-17.
-
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
10/5/2022
Cue Biopharma, Inc. announced three poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, to be held in Boston, Massachusetts and virtually on November 8-12, 2022.
-
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
10/4/2022
Cue Biopharma, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to CUE-101, its lead clinical drug candidate from the CUE-100 series of interleukin 2 -based biologics, for the treatment of patients with human papilloma virus recurrent/metastatic head and neck squamous cell carcinoma as a monotherapy and in combination with pembrolizumab.
-
Cue Biopharma to Present at Two September 2022 Scientific Conferences
9/7/2022
Cue Biopharma, Inc. announced members of their management and scientific teams will participate in two scientific conferences this September, The Promise of Interleukin-2 Therapy taking place September 14-17 in Paris, France and the Next Generation Protein Therapeutics Summit, held in Boston, Massachusetts and virtually on September 28-30.
-
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers
8/22/2022
Cue Biopharma, Inc. announced today that it has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102, its second clinical drug candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics.
-
Cue Biopharma Reports Second Quarter 2022 Financial Results
8/4/2022
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today second quarter 2022 financial results.
-
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
7/11/2022
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the Guggenheim I&I Spotlight Series – Treg-based Therapies being held July 12–13, 2022.
-
Cue Biopharma to Present at the JMP Securities Life Sciences Conference
6/13/2022
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 15–16, 2022.
-
More oncology firms presented positive developments in their respective cancer research programs at the 2022 ASCO annual meeting this week.
-
Cue Biopharma to Present at the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced that it will present at the Jefferies Healthcare Conference being held June 8–10, 2022.
-
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2022
Cue Biopharma, Inc. announced it will give a poster presentation at the American Society of Clinical Oncology Annual Meeting to be held in-person June 3–7 at the McCormick Place Convention Center in Chicago, Illinois and virtually.
-
On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
-
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers
5/11/2022
Cue Biopharma, Inc. (Nasdaq: CUE), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for the evaluation of CUE-102, its second interleukin 2 (IL-2)-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase 1 trial.